



REVA to Present Fantom 24-Month Data at TCT 2017

San Diego, California (Monday, October 23, 2017 - PDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce the Company’s scheduled presentations during the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, being held October 29th through November 2nd in Denver, Colorado.

The Company will release new data on the *Fantom*[®] bioresorbable scaffold (“BRS”), the only bioresorbable scaffold made from Tyrocore™, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. 24-month data on a subset of patients from the FANTOM II clinical trial will be presented by trial investigator, Dr. Ricardo A. Costa, from Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, and Dr. James B. Hermiller Jr., from the Heart Center of Indiana in Indianapolis, Indiana.

The complete schedule of REVA’s presentations is as follows:

Tuesday, October 31, 2017

10:18 a.m.	Moderated Poster Session: New BRS
Moderated Posters 4 Exhibit Hall	<i>FANTOM II Trial: First Report on Initial 24 Month Outcomes</i> Presented by Dr. Ricardo A. Costa
4:43 p.m.	Didactic Session: BVS, Part 1 – Devices and Emerging Data
Mile High Ballroom	<i>Fantom: A Radiopaque “Stent-Like” BRS with Improved Expansion Characteristics</i> Presented by Dr. James B. Hermiller, Jr.

Wednesday, November 1, 2017

10:00 to 11:00 a.m.	Poster Presentation
Exhibit Hall	<i>12-month Angiographic and Clinical Follow-up of the Fantom Scaffold</i> Presented by Dr. Georgios Bouras

The clinical data presented at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com following the presentations. The clinical results will also be lodged with the Australian Securities Exchange and filed with the US Securities and Exchange Commission.

About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed and commercialized a proprietary drug-eluting bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. The Company’s *Fantom*[®]

scaffold received European CE Marking on April 3, 2017. It is designed with thin struts while maintaining strength and distinct ease-of-use features including complete scaffold visibility under x-ray and expansion with one continuous inflation.

United States**Investor & Media Enquiries:**

REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia**Investor Enquiries:**

Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia**Media Enquiries:**

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722